Guggenheim reiterates Cabaletta Bio stock rating on trial data

Cabaletta Bio reported encouraging early data from its rese-cel CAR-T trial, including complete B-cell depletion in 3 of 4 refractory pemphigus vulgaris patients and treatment-free status in 3 of 4, with only one Grade 1 CRS event and no neurotoxicity. Guggenheim reiterated a Buy rating and $16 price target, while the company also completed a $150 million financing and signed a 10-year manufacturing agreement with Cellares. The data support expansion of the RESET-PV trial and keep key readouts on track for the second half of 2026 and first half of 2026 in lupus.

Analysis

CABA is transitioning from a binary science story to a capital-formation and execution story, which is a better setup for multiple expansion if the next two readouts are clean. The higher-dose cohorts matter more than the initial data: investors will pay for evidence that the no-preconditioning approach can preserve efficacy while improving logistics and safety, because that is what expands the addressable market beyond academic-center outliers and into a repeatable commercial platform.

The financing plus supply agreement reduce near-term existential risk, but they also remove the main scarcity premium in the stock: the market no longer needs to price in a dilutive near-term raise or manufacturing bottleneck. That shifts the debate to durability, redosing, and whether autoimmune indications can generate a clinically meaningful treatment-free interval versus a one-and-done hematology-style CAR-T narrative. If durability slips or the safety profile worsens at higher dose, the equity could re-rate sharply lower because the platform thesis would be impaired rather than merely delayed.

Second-order, the real winners are likely enabling-technology partners and contract manufacturers if CABA proves that scaled autoimmune CAR-T can be produced without bespoke infrastructure. That would pressure smaller cell-therapy peers still dependent on highly manual manufacturing, while also giving large-cap biotech licensors a blueprint for lower-capex commercialization. The market is likely underestimating how much the Lilly association can help de-risk future partnering, but overestimating how quickly this can become a large revenue story; the timeline here is still measured in data readouts over the next 6-15 months, not quarters.

Key Decisions for Investors

• Maintain a tactical long in CABA only into the next two catalysts: RESET-SLE initial data in 1H26 and RESET-PV durability in 2H26; expect 25-40% upside on clean safety/efficacy, but use a hard stop if higher-dose cohorts show worsening CRS/ICANS or no incremental response.
• Sell downside via put spreads in CABA around post-financing stabilization if implied vol remains elevated; the balance sheet now reduces bankruptcy risk, so skew should compress if the next readout is merely 'good, not great.'
• Pair trade: long CABA / short a basket of manual-process cell therapy names with tighter financing risk; thesis is that manufacturing scalability will become the differentiator as the market rewards capital efficiency over pure pipeline breadth over the next 6-12 months.
• If already long, take partial profits into any pre-data spike and re-add on pullbacks after the initial lupus readout; the stock is likely to trade on headline beta until durability data confirms whether the platform is actually repeatable.